Abstract:BACKGROUND:Hepatitis B virus (HBV) infection is the primary cause of hepatitis with chronic HBV infection, which may develop into liver fibrosis, cirrhosis and hepatocellular carcinoma. Detection of early-stage fibrosis related to HBV infection is of great clinical significance to block the progression of liver lesion. Direct liver biopsy is regarded as the gold standard to detect and assess fibrosis; however, this method is invasive and prone to clinical sampling error. In order to address these issues, we attempted to find more convenient and effective serum markers for detecting HBV-induced early-stage liver fibrosis.AIM:To investigate serum N-glycan profiling related to HBV-induced liver fibrosis and verify multiparameter diagnostic models related to serum N-glycan changes.METHODS:N-glycan profiles from the sera of 432 HBV-infected patients with liver fibrosis were analyzed. Significant changed N-glycan levels (peaks) (P < 0.05) in different fibrosis stages were selected in the modeling group, and multiparameter diagnostic models were established based on changed N-glycan levels by logistic regression analysis. The receiver operating characteristic (ROC) curve analysis was performed to evaluate diagnostic efficacy of N-glycans models. These models were then compared with the aspartate aminotransferase to platelet ratio index (APRI) , fibrosis index based on the four factors (FIB-4), glutamyltranspeptidase platelet albumin index (S index), GlycoCirrho-test, and GlycoFibro-test. Furthermore, we combined multiparameter diagnostic models with alanine aminotransferase (ALT) and platelet (PLT) tests and compared their diagnostic power. In addition, the diagnostic accuracy of N-glycan models was also verified in the validation group of patients.RESULTS:Multiparameter diagnostic models constructed based on N-glycan peak 1, 3, 4 and 8 could distinguish between different stages of liver fibrosis. The area under ROC curves (AUROCs) of Model A and Model B were 0.890 and 0.752, respectively differentiating fibrosis F0-F1 from F2-F4, and F0-F2 from F3-F4, and surpassing other serum panels. However, AUROC (0.747) in Model C used for the diagnosis of F4 from F0-F3 was lower than AUROC (0.795) in FIB-4. In combination with ALT and PLT, the multiparameter models showed better diagnostic power (AUROC = 0.912, 0.829, 0.885, respectively) when compared with other models. In the validation group, the AUROCs of the three combined models (0.929, 0.858, and 0.867, respectively) were still satisfactory. We also applied the combined models to distinguish adjacent fibrosis stages of 432 patients (F0-F1/F2/F3/F4), and the AUROCs were 0.917, 0.720 and 0.785.CONCLUSION:Multiparameter models based on serum N-glycans are effective supplementary markers to distinguish between adjacent fibrosis stages of patients caused by HBV, especially in combination with ALT and PLT.

[The Diagnostic Value of Eight Serum Indices for Liver Fibrosis].

Diagnostic Value of Platelet Derived Growth Factor-Bb, Transforming Growth Factor-Beta 1, Matrix Metalloproteinase-1, and Tissue Inhibitor of Matrix Metalloproteinase-1 in Serum and Peripheral Blood Mononuclear Cells for Hepatic Fibrosis

The Diagnostic Value of the Fib-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis

Biomarkers of liver fibrosis detecting with electrochemical immunosensor on clinical serum

Serological Diagnosis Of Liver Fibrosis By Quantitative Estimation Of Serum Biomarkers Using Luminex Xmap Assay

Determination of Serum Fibrosis Indexes in Patients with Chronic Hepatitis and Its Significance

[Serum Fibrosis Markers in Diagnosing Liver Fibrosis].

ROC Curves in Evaluation of Serum Fibrosis Indices for Hepatic Fibrosis.

Application Analysis on Detection of Four Serum Indicators with a Domestic Chemiluminescence Reagent in Liver Fibrosis Diagnosis

Serological Indices and Ultrasound Variables in Predicting the Staging of Hepatitis B Liver Fibrosis: A Comparative Study Based on Random Forest Algorithm and Traditional Methods.

Clinical Significance of Serum Transforming Growth Factor-β_1 on Diagnose of Liver Fibrosis

Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid

Clinical value of real-time elastography quantitative parameters in evaluating the stage of liver fibrosis and cirrhosis.

ROC curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis

Evaluation and comparison of the diagnostic performance of routine blood tests in predicting liver fibrosis in chronic hepatitis B infection.

Serum N-glycan Markers for Diagnosing Liver Fibrosis Induced by Hepatitis B Virus

Role of Hyaluronic Acid and Laminin As Serum Markers for Predicting Significant Fibrosis in Patients with Chronic Hepatitis B.

Evaluation of serum non-invasive methods for the diagnosis of liver fibrosis in patients with chronic hepatitis B virus infection

Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China

Value of Five Noninvasive Serum Models in the Diagnosis of Chronic Hepatitis B Liver Fibrosis

The Study on Serologic Index of Hepatic Fibrosis in Viral Hepatitis